Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study
Open Access
- 1 June 2017
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 188, 73-81
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Treatment with Adenosine Diphosphate Receptor Inhibitors—Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study design: Expanding the paradigm of longitudinal observational researchAmerican Heart Journal, 2011
- Optimal caliper widths for propensity‐score matching when estimating differences in means and differences in proportions in observational studiesPharmaceutical Statistics, 2011
- Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCIJAMA, 2010
- Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysisThe Lancet, 2010
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelNew England Journal of Medicine, 2009
- Constructing Inverse Probability Weights for Marginal Structural ModelsAmerican Journal of Epidemiology, 2008
- General Cardiovascular Risk Profile for Use in Primary CareCirculation, 2008
- Studying Prescription Drug Use and Outcomes With Medicaid Claims DataMedical Care, 2007
- Challenges of Using Medical Insurance Claims Data for Utilization AnalysisAmerican Journal of Medical Quality, 2006
- Reducing Bias in Observational Studies Using Subclassification on the Propensity ScoreJournal of the American Statistical Association, 1984